Joint health: “boomer” and “millennial” demographics hold future potential, says Lonza exec


19 Oct 2018 --- The global market for joint health supplements is increasing, driven by the large “baby boomer” population seeking to maintain their mobility and the high rate of supplement use among “millennials.” This is according to Dominik Mattern, Associate Director and Head of Business Development at Lonza. During a NutritionInsight webinar presented yesterday, entitled Driving growth in the joint health category: UC-II undenatured Type II collagen for joint support, Mattern highlighted the shifting market dynamics which is supporting the popularity of ingredients for joint health such as Lonza's UC-II undenatured Type II collagen.

“Two generations that I would like to draw attention to are the boomers, who look to maintain their health and are looking for solutions to do so. In that respect, UC-II undenatured Type II collagen is a game changer. It has a unique mode of action and it will play a role. The other generation are the millennials, they have a high use of supplements and they are continuously looking into effective solutions,” explains Mattern.

“This ingredient is really for the global consumer,” says Stephane Vouche, Marketing Manager at Lonza. “The largest market at the moment for joint health is Asia, followed by the Americas and European countries such as Germany, France, the UK and Italy,” he adds.

Click to Enlarge
Percentage of EU consumers who would be likely to use
joint health supplements - by country.

The joint health market has been diversifying and moving beyond encompassing just seniors for some time. Innova Market Insights data highlights that mobility is one of the top concerns for UK and US consumers, while products featuring mobility claims accounted for almost 17 percent of all supplements tracked globally between 2013 and 2017.

One ingredient that has potential for this diversifying market is UC-II undenatured Type II collagen, as highlighted by Lonza in the webinar.

UC-II undenatured Type II collagen
Hoping to tap into the high potential consumer segments for joint health – the boomers and the millennials – Lonza offers its UC-II. The ingredient has seen an annual growth from 25 percent to 58 percent from 2013 to 2017, according to Lonza. In this way, its growth rates are similar to that of other trending ingredients such as probiotics and curcumin, the company further notes.

Undenatured (native) type II collagen is derived from chicken sternum cartilage. It’s a trademarked, patented and clinically studied ingredient for joint health. 

“The ingredient is absorbed in the gut, in an area called the Peyers patch. It initiates a cell-signaling cascade involving all anti-inflammatory cytokines (TGF-B and IL-10) which then trigger chondrocytes to produce type II collagen and other extracellular matrix proteins in the knee,” Vouche explains.

Click to Enlarge
UC-II can be combined with vitamins or botanical extracts,
such as curcumin, in capsule form using Lonza's duocap.

Natural ingredients, such as collagen, are particularly popular for joint health. The company describes the ingredient's unique selling points as its small daily dose, unique mechanism of action (oral tolerance) and its considerable backing of preclinical and clinical science. This includes its effect in modulating knee osteoarthritis symptoms and improvements in knee function in healthy subjects.

NutritionInsight has previously reported on how low dosage forms are trending in the joint health market. Consumers are increasingly looking for products that offer efficacy in a convenient format. Furthermore, the “boomer” demographic are often already taking a higher number of medications, often in the form of pills. Taking more medications for joint health is far less attractive than natural supplements, for more consumers.

The low dosage form of the ingredient makes it suitable for a range of applications and delivery forms, further strengthening its appeal to consumers who may tire from taking a large number of medications. 

“One of the biggest differentiators of the UC-II from the more common joint health ingredients is the small daily dose. Solutions already on the US market of our ingredient support this,” says Vouche.

One ready to market product in the US containing UC-II includes vitamin C and D, manganese and copper. Adding vitamin K2 could also be an opportunity, as well as botanical extracts with anti-inflammatory benefits such as omega 3, krill oil, curcumin or Boswellia, Vouche adds. Lonza’s duocap capsule technology [from the legacy Capsugel business], which is suited for combination or dual release products, could facilitate such combinations. 

You can access the full webinar here.

By Laxmi Haigh

To contact our editorial team please email us at



Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment. 

Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. 

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources. 

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Related Articles

Health & Nutrition News

Lipid-based supplement found to benefit psychomotor development in children

18 Jan 2019 --- A recent study has found that a new lipid-based nutrient supplement may positively impact the development of older infants. The study, published in The American Journal of Clinical Nutrition, is the joint effort of DSM, the North West University of South Africa, the Global Alliance for Improved Nutrition (GAIN) and Unilever. The findings revealed that children who consumed the supplement showed enhanced growth and psychomotor development, as well as high iron levels.

Health & Nutrition News

Weekly Roundup: Fiber-fortification for select Tesco own-label foods, Lonza gains investment grade rating

18 Jan 2019 --- In nutrition news this week, Stratum Nutrition has been accepted as a “Preferred Supplier” by the National Animal Supplement Council (NASC) for its eggshell and curcumin brands, while the Council for Responsible Nutrition (CRN) has appointed a new chair to the board of directors. Lonza has received an investment grade rating from US financial services company Standard & Poor's. In research updates, a new study suggests that tart cherry juice may help reduce the risk of inflammation associated with many chronic diseases, including cardiovascular disease. Increasing customer interest in fortified foods has prompted Tesco to begin boosting the fiber content in some of its most popular snacks.

Health & Nutrition News

Has the haze lifted? As cannabis-derivatives get the green light, NPD expansion is set to grow

15 Jan 2019 --- Cannabis-derivatives, such as hemp and cannabidiol (CBD), have been increasingly cropping up on ingredients lists in the US and elsewhere. A recent ruling, which came as the US Government launched its farm bill in December 2018, alleviates hemp of its illegal status, which is expected to spur further innovation. Part one of this NutritionInsight two-part report into cannabis-derived products in the nutrition and food industry explored the softening regulatory environment. Part two considers how the industry may respond to the opportunities that such regulation shifts may bring to the US and Canada, for example.

Health & Nutrition News

Eating our hearts out? European dietary habits are causing high CVD and premature death levels, study says

14 Jan 2019 --- Nearly half of premature cardiovascular (CVD) deaths in Europe could be prevented by better nutrition. This is the conclusion of a joint study at Germany’s  Martin Luther University Halle-Wittenberg (MLU), the Friedrich Schiller University Jena, the nutriCARD competence cluster and the University of Washington, US. Published in the European Journal of Epidemiology, the study calls for policy interventions to increase prevention of cardiovascular diseases (CVD) through better diets and education.

Health & Nutrition News

Mandatory fortification boost: Vitamin D supplements linked to reduced risk of lung attacks in COPD patients

11 Jan 2019 --- Vitamin D supplementation could reduce the risk of lung attacks in patients suffering from Chronic Pulmonary Disease (COPD) according to a new study by Queen Mary University of London. The researchers found that the use of vitamin D supplements led to a 45 percent reduction in lung attacks among COPD patients who were deficient in vitamin D. No benefit was seen for patients with higher vitamin D levels.

More Articles